Several studies in mice have shown that treatment with liraglutide, a long-acting palmitoylated analog of GLP-1, alleviates hepatic steatosis and has great potential to inhibit NASH or NAFLD (160, 161, 167, 168). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.